Use of Angiotensin-(1-7) in COVID-19

• Status: Completed
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The renin-angiotensin system (RAS) has a relevant role in COVID-19, as the virus will enter host's cells via the angiotensin-converting enzyme 2 (ACE2); RAS disequilibrium might also play a key role in the modulation of the inflammatory response that characterizes the lung involvement. Angiotensin-(1-7) is a peptide that could be altered in COVID-19 patient and its supplementation may potentially helpful in this setting.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Erasme University Hospital
• Collaborators: Angitec; Federal University of Minas Gerais; Fonds Erasme pour la Recherche Medicale
• Treatments: Angiotensin I (1-7)

Criteria

Inclusion Criteria:

• Admission to the Intensive Care Unit with severe pneumonia criteria (clinical signs of pneumonia + one of the following criteria: respiratory rate greater than 30/minute; signs of respiratory effort, SatO2 < 90% in room air);

• COVID-19 confirmed or highly suspicious (positive contact or suggestive image)

Exclusion Criteria:

• Diagnosed with cancer (at any stage);

• Hemodynamic instability (need for vasopressors);

• Pregnant women; Immunocompromised patients;

• Palliative Care;

• Inclusion in any other interventionist study;

• Heart failure as a predominant cause of acute respiratory failure;

• Decompensated liver cirrhosis;

• HIV +;

• Dialysis;

• Home / long-term oxygen therapy;

• Idiopathic pulmonary fibrosis